Direkt zum Inhalt
Merck

Fortfahren mit

350R-2

FOXP1 (EP137) Rabbit Monoclonal Primary Antibody

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis

Über diesen Artikel

UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
EP137, monoclonal
Application:
IHC (p)
Citations:
9
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP137, monoclonal

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (350R-24), vial of 0.1 mL concentrate Research Use Only (350R-24-RUO), vial of 0.5 mL concentrate (350R-25), vial of 1.0 mL concentrate (350R-26), vial of 1.0 mL concentrate Research Use Only (350R-26-RUO), vial of 1.0 mL pre-dilute Research Use Only (350R-27-RUO), vial of 1.0 mL pre-dilute ready-to-use (350R-27), vial of 7.0 mL pre-dilute ready-to-use (350R-28), vial of 7.0 mL pre-dilute ready-to-use Research Use Only (350R-28-RUO)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)

isotype

IgG

control

lymph node, tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Gene Information

human ... FOXP1(27086)

General description

Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique.[1] Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL.[1][2][3] The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies.[2] Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform,[4][5][6][7][8] using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Analysis Note


IVD

IVD

IVD

RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: [email protected]
FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Probieren Sie unser Produkt-Auswahlhilfe, um Ihre Auswahl einzugrenzen


Lagerklasse

12 - Non Combustible Liquids

wgk

WGK 2



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



A A Alizadeh et al.
Nature, 403(6769), 503-511 (2000-02-17)
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
William W L Choi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5494-5502 (2009-08-27)
Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies



Questions

Reviews

No rating value

Active Filters